drugset / Trial / NCT06208657
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Phase 1/2
Recruiting
90 enrolled
Australian & New Zealand Children's Haematology/Oncology Group
Bristol-Myers Squibb · collabC17 Council · collabKazia Therapeutics Limited · collabMedical Research Future Fund · collabStand Up To Cancer · collabThe Hospital for Sick Children · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A companion platform trial to test novel targeted agents based on the patient's tumor profile.
Timeline
- Start
- 2024-07-10
- Primary completion
- 2030-12
- Completion
- 2035-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | Paxalisib | Small molecule | 21 mg/m2 | Oral |
| Subject | Relatlimab | Monoclonal antibody | 160 mg | Intravenous |
| Subject | Temozolomide | Small molecule | 150 mg/m2 | Oral |